Jefferies notes the U.S. Preventive Services Task Force is expected to publish revised guidelines for colorectal cancer screening in the coming months, which will include an assessment of Exact Sciences' Cologuard. After speaking with a former affiliate of the USPSTF's review board, Jefferies has greater confidence that Cologuard can receive an A or B rating. Such a rating would mandate private payor coverage and "all but ensure" a premium average selling price of above $500 per test, Jefferies tells investors in a research note. It sees "significant upside for the stock" on a favorable outcome. The firm keeps a Buy rating on Exact Sciences with a $33 price target.